The CAMI-1 study introduces a new clinical tool: CRP apheresis may prove its usefulness in the treatment of inflammatory diseases such as other subtypes of acute coronary syndromes (53) and stroke (54, 55), in which CRP might be causally involved. The gene discussed is CRP; the disease is Stroke.